Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSM265 Prophylaxis in Controlled Human Malaria Infection
NCT02562872Phase 1Completed
- Sponsor
- Medicines for Malaria Venture
- Start
- Mar 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DSM265 in malaria (6 cohorts), sponsored by Medicines for Malaria Venture. Primary endpoints: Number of subjects with positive parasitemia at 28 days and Time interval between challenge and the first positive parasitemia at 28 days. Started Mar 2016; status: completed.
02
Drugs
DSM265
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02562872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562872.